Clinical trials: Gastric Cancer Peritoneal Metastases, open to volunteers
Gastric Cancer, Peritoneal Metastases
HIPEC Combined Gastrectomy in Patients With Advanced Gastric Cancer Received Neoadjuvant Chemotherapy
Patients with stage cT3-4N+M0 gastric cancer were recommended to receive neoadjuvant chemotherapy before radical surgery in terms of the eradication of micrometastasis in addition to local control, higher compliance with…
- Trial name
- NCT05300945
- Testing
- HIPEC
- Volunteers
- 200 people
- Sponsor
- Zhixin Cao
Advanced Gastric Cancer
Evaluation of Pressurized Intraperitoneal Aerosol Chemotherapy With VRT106 Versus PIPAC in Patients With Advanced Gastric Cancer and PeritonealMetastasis: A Prospective, Multicenter, Open-Label, Randomized Controlled Trial
This study is a prospective, multicenter, open-label, randomized controlled clinical trial, planned to enroll 30 patients with advanced gastric cancer and peritoneal metastasis.
- Trial name
- NCT07486310
- Testing
- Doxorubicin (Adriamycin), VRT106
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Guangdong Provincial People's Hospital
Gastric Cancer, Metastatic
Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Management Of Gastric Cancer Metastatic To The Peritoneum
The goal of this clinical research study is to study the recommended dose of TROP2 CAR/IL-15 TGFBR2 KO NK cells that can be given intraperitoneally (infused directly into the stomach area) to participants with adenocarcinoma of…
- Trial name
- NCT07509008
- Testing
- TGFBR2 KO CAR27/IL-15 NK cells, Rimiducid (AP1903), Fludarabine
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- M.D. Anderson Cancer Center
Gastric Cancer
A Clinical Study Evaluating the Efficacy of Systemic Chemotherapy and Immune Checkpoint Inhibitors Combined With Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Gastric Cancer Patients With Peritoneal Metastasis
This study is a single-center, prospective, phase II clinical trial aimed at assessing the impact of HIPEC combined with systemic chemotherapy and immune checkpoint inhibitors on the R0 resection rate in patients with peritoneal…
- Trial name
- NCT06685887
- Testing
- HIPEC, SOX, Immune Checkpoint Inhibitors
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Gastric Cancer (Diagnosis)
Application of Intraperitoneal Hyperthermic Chemotherapy in the Treatment of Gastric Cancer With Peritoneal Metastasis
This clinical study is designed to evaluate a combined treatment approach in adults with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma that has spread to the peritoneum (peritoneal metastasis), as confirmed…
- Trial name
- GCPM-HIPEC (NCT07904442)
- Testing
- Retlirafusp alfa + nab-paclitaxel + apatinib, HEPIC
- Volunteers
- 32 people
- Sponsor
- Anhui Provincial Cancer Hospital
Peritoneal Metastasis of Gastric and Colorectal Cancer, LDRT
LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer
There have been initial explorations on the treatment of peritoneal metastasis of gastric and colorectal cancer both at home and abroad.
- Trial name
- TRIUNITE06 (NCT07453875)
- Testing
- LDRT, SOX or CAPOX regimen, Tislelizumab
- Where
- 2 sites in China
- Volunteers
- 9 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Gastric Cancer Stage IV, Peritoneal Metastases From Gastric Cancer
LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study
In this study, the investigators will use LM-302 and S-1 plus intraperitoneal paclitaxel with or without Cadonilimab to treat Claudin 18.2-positive gastric or gastroesophageal junction adenocarcinoma with peritoneal metastasis.
- Conditions
- Gastric Cancer Stage IV, Peritoneal Metastases From Gastric Cancer, Gastric or Esophagogastric Junction Adenocarcinoma
- Trial name
- NCT07556640
- Testing
- LM-302, S-1, paclitaxel, LM-302, Cadonilimab, S-1, paclitaxel
- Where
- China
- Volunteers
- 74 people
- Sponsor
- Ruijin Hospital
Gastric Cancer, Metastatic
A Clinical Study of BioTTT001 in Combination With SOX and Toripalimab in Patients With Gastric Cancer
This is a phase I, single arm, open-label clinical study of BioTTT001 in combination with SOX and Toraplizumab in patients with peritoneal metastases from gastric cancer.
- Trial name
- NCT06283121
- Testing
- BioTTT001 intraperitoneal infusion, SOX regimen, toripalimab
- Volunteers
- 30 people
- Sponsor
- China Medical University, China
Gastric Cancer (GC)
GK01 Cell Therapy in Gastric Cancer With Peritoneal Metastasis
This study is a single-arm, open-label clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of GK01 cell therapy in patients with gastric cancer and peritoneal metastasis.
- Trial name
- NCT07923396
- Testing
- GK01 combination with nab-paclitaxel and S-1
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Ruijin Hospital
Gastric Cancer Peritoneal Metastases
A Prospective, Phase II Clinical Study of HIPEC Combined With NIPS and Tislelizumab Conversion Therapy for Gastric Cancer With Peritoneal Metastasis With Positive Cytology Alone or PCI Score ≤10
This study aims to evaluate the efficacy and safety of HIPEC combined with NIPS and tislelizumab conversion therapy for gastric/gastroesophageal junction cancer with positive cytology alone (CY1P0) or a Peritoneal Carcinomatosis…
- Trial name
- NCT07304258
- Testing
- HIPEC, NIPS, Paclitaxel Injection, S-1, tislelizumab
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Hebei Medical University
NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC)
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine…
- Conditions
- NSCLC Adenocarcinoma, Gastroesophageal Cancer (GC), Gastric Adenocarcinoma, Adenocarcinoma of Esophagus
- Trial name
- NCT07277413
- Testing
- IDE892, IDE397
- Where
- 23 sites in United States
- Volunteers
- 260 people
- Sponsor
- IDEAYA Biosciences
Peritoneal Metastases From Gastric Cancer
INTERACT Stomach-II
This is a phase II study conducted in three hospitals in the Netherlands (Erasmus MC in Rotterdam, Catharina Hospital in Eindhoven, and the Netherlands Cancer Institute in Amsterdam). A total of 55 patients will take part.
- Trial name
- NCT07133490
- Testing
- intraperitoneal chemotherapy
- Where
- 3 sites in Netherlands
- Volunteers
- 55 people
- Sponsor
- Erasmus Medical Center
Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
This phase I trial studies the side effects of pressurized intraperitoneal aerosol chemotherapy (PIPAC) in treating patients with ovarian, uterine, appendiceal, stomach (gastric), or colorectal cancer that has spread to the…
- Conditions
- Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Malignant Uterine Neoplasm
- Trial name
- NCT04329494
- Testing
- Biopsy, Cisplatin, Doxorubicin
- Where
- 3 sites in United States
- Volunteers
- 49 people
- Sponsor
- City of Hope Medical Center
Pancreatic Cancer, Thyroid Cancer
Integrated Cancer Repository for Cancer Research
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer…
- Conditions
- Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer
- Trial name
- iCaRe2 (NCT02012699)
- Where
- 42 sites in United States
- Volunteers
- 999,999 people, healthy volunteers welcome
- Sponsor
- University of Nebraska
Gastric (Stomach) Cancer
Development of a Predictive Model for Gastric Cancer Peritoneal Metastasis and Cachexia Using BUB1 and Radiopathomics Data With Deep Learning
This clinical trial aims to develop a predictive model for gastric cancer (GC) peritoneal metastasis and cachexia by integrating BUB1 gene data with radiological and pathological data using advanced deep learning techniques.
- Trial name
- BUDDLE (NCT06858644)
- Testing
- BUB1-Integrated Deep Learning Model for Gastric Cancer Metastasis and Cachexia Prediction
- Volunteers
- 500 people
- Sponsor
- Qun Zhao
Cancer
Detection of Peritoneal Metastasis of Gastric Cancer by Liquid Biopsy in Peripheral Blood: A Prospective Study
This study is a prospective, multi-omics, observational study aimed at detecting peritoneal metastasis of gastric cancer by combined assays for methylation of cell-free DNA (cfDNA) and other blood-based biomarkers.
- Trial name
- NCT05347524
- Testing
- Baseline blood draw and blood-based biomarkers analyses
- Where
- China
- Volunteers
- 384 people
- Sponsor
- Shanghai Zhongshan Hospital
Gastric Cancer Peritoneal Metastasis (GCPM)
A Sequential Trial of Low-Dose Radiotherapy Followed by Concurrent Immunotherapy, Systemic Chemotherapy, and Intraperitoneal Perfusion in Gastric Cancer With Peritoneal Carcinomatosis
This study is a prospective, single-center, open-label, exploratory phase II clinical trial aimed at evaluating the safety, tolerability, and preliminary efficacy of low-dose radiotherapy (LDR) sequentially combined with…
- Trial name
- NCT07784413
- Testing
- low-dose radiotherapy (LDR) sequentially combined with serplulimab, bevacizumab analog, and irinotecan or albumin-bound paclitaxel
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Zhejiang Cancer Hospital
Gastric Cancer
Biomarker Analysis of HIPEC Combined With PD1/PDL1 Inhibitor for Gastric Cancer With Peritoneal Metastasis
A single-center, observational study, integrated biomarker analysis of HIPEC combined Programmed cell death 1 /Programmed cell death 1 ligand 1(PD1/PDL1)inhibitor in previously treated patients of advanced gastric cancer with…
- Trial name
- NCT05661110
- Testing
- Observational
- Volunteers
- 46 people
- Sponsor
- Affiliated Cancer Hospital & Institute of Guangzhou Medical University
Gastric Cancer with Peritoneal Metastasis
Tislelizumab Combined with SOX and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Gastric Cancer with Peritoneal Metastasis: a Prospective Cohort Study
The clinical trial aims to assess the efficacy and safety of Tislelizumab combined with the SOX regimen and HIPEC in treating gastric cancer with peritoneal metastasis.
- Trial name
- NCT06682182
- Testing
- Tislelizumab+SOX
- Volunteers
- 74 people
- Sponsor
- Southwest Hospital, China
Gastric Neoplasms, Esophageal Cancer
Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors
This research study aims to evaluate the safety and determine the optimal dose of a new experimental drug, vvDD-hIL2 (vaccinia virus double-deleted human interleukin 2), in patients with advanced abdominal cancer.
- Conditions
- Gastric Neoplasms, Esophageal Cancer, Liver Cancer, Liver Metastasis
- Trial name
- RIOT3 (NCT07001592)
- Testing
- vvDD-hIL-2-RG-1
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)